Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Ovarian Neoplasms

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 76 articles: HTML format

Single Articles

October 2023
1. BHAMIDIPATI D, Haro-Silerio JI, Yap TA, Ngoi N, et al
   PARP inhibitors: enhancing efficacy through rational combinations.
   Br J Cancer. 2023;129:904-916.
   PubMed     Abstract available
   
   
   August 2023
2. CHOI JA, Kim H, Kwon H, Lee EH, et al
   Ascitic autotaxin as a potential prognostic, diagnostic, and therapeutic target for epithelial ovarian cancer.
   Br J Cancer. 2023 Aug 18. doi: 10.1038/s41416-023-02355.
   PubMed     Abstract available
   
   
   
3. JOHNSON CE, Alberg AJ, Bandera EV, Peres LC, et al
   Association of inflammation-related exposures and ovarian cancer survival in a multi-site cohort study of Black women.
   Br J Cancer. 2023 Aug 3. doi: 10.1038/s41416-023-02385.
   PubMed     Abstract available
   
   
   July 2023
4. LEE JE, Kim KT, Shin SJ, Cheong JH, et al
   Genomic and evolutionary characteristics of metastatic gastric cancer by routes.
   Br J Cancer. 2023 Jul 8. doi: 10.1038/s41416-023-02338.
   PubMed     Abstract available
   
   
   June 2023
5. YANG Z, Wang XL, Bai R, Liu WY, et al
   Retraction Note: miR-23a promotes IKKalpha expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells.
   Br J Cancer. 2023 Jun 26. doi: 10.1038/s41416-023-02328.
   PubMed    
   
   
   April 2023
6. QUINTELA M, James DW, Garcia J, Edwards K, et al
   In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer.
   Br J Cancer. 2023 Apr 29. doi: 10.1038/s41416-023-02274.
   PubMed     Abstract available
   
   
   
7. O'MAHONY DG, Ramus SJ, Southey MC, Meagher NS, et al
   Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.
   Br J Cancer. 2023 Apr 19. doi: 10.1038/s41416-023-02263.
   PubMed     Abstract available
   
   
   
8. MARTIN AL, Colin-Leitzinger CM, Sinha SK, Chern JY, et al
   Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer.
   Br J Cancer. 2023 Apr 6. doi: 10.1038/s41416-023-02259.
   PubMed     Abstract available
   
   
   March 2023
9. LONG X, Lu H, Cai MC, Zang J, et al
   APOBEC3B stratifies ovarian clear cell carcinoma with distinct immunophenotype and prognosis.
   Br J Cancer. 2023 Mar 30. doi: 10.1038/s41416-023-02239.
   PubMed     Abstract available
   
   
   February 2023
10. WALKER TDJ, Faraahi ZF, Price MJ, Hawarden A, et al
    The DNA damage response in advanced ovarian cancer: functional analysis combined with machine learning identifies signatures that correlate with chemotherapy sensitivity and patient outcome.
    Br J Cancer. 2023 Feb 21. doi: 10.1038/s41416-023-02168.
    PubMed     Abstract available
    
    
    
11. GUFFANTI F, Alvisi MF, Anastasia A, Ricci F, et al
    Correction to: Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    Br J Cancer. 2023 Feb 16. doi: 10.1038/s41416-023-02205.
    PubMed    
    
    
    
12. COLOMBO N, Gadducci A, Sehouli J, Rulli E, et al
    INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 m
    Br J Cancer. 2023 Feb 9. doi: 10.1038/s41416-022-02108.
    PubMed     Abstract available
    
    
    January 2023
13. KRALJ J, Pernar Kovac M, Dabelic S, Polancec DS, et al
    Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT.
    Br J Cancer. 2023 Jan 30. doi: 10.1038/s41416-023-02140.
    PubMed     Abstract available
    
    
    
14. TAKAMATSU S, Yoshihara K, Baba T, Shimada M, et al
    Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.
    Br J Cancer. 2023 Jan 2. doi: 10.1038/s41416-022-02122.
    PubMed     Abstract available
    
    
    December 2022
15. SANDVEI MS, Pinborg A, Gissler M, Bergh C, et al
    Risk of ovarian cancer in women who give birth after assisted reproductive technology (ART)-a registry-based Nordic cohort study with follow-up from first pregnancy.
    Br J Cancer. 2022 Dec 22. doi: 10.1038/s41416-022-02097.
    PubMed     Abstract available
    
    
    
16. KRISTELEIT RS, Drew Y, Oza AM, Domchek SM, et al
    Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
    Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02022.
    PubMed     Abstract available
    
    
    
17. MURUMAGI A, Ungureanu D, Khan S, Arjama M, et al
    Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
    Br J Cancer. 2022 Dec 7. doi: 10.1038/s41416-022-02067.
    PubMed     Abstract available
    
    
    November 2022
18. BAX HJ, Chauhan J, Stavraka C, Santaolalla A, et al
    Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes.
    Br J Cancer. 2022 Nov 19. doi: 10.1038/s41416-022-02031.
    PubMed     Abstract available
    
    
    
19. WEIR A, Kang EY, Meagher NS, Nelson GS, et al
    Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.
    Br J Cancer. 2022 Nov 2. pii: 10.1038/s41416-022-02014.
    PubMed     Abstract available
    
    
    September 2022
20. OCHS-BALCOM HM, Johnson C, Guertin KA, Qin B, et al
    Racial differences in the association of body mass index and ovarian cancer risk in the OCWAA Consortium.
    Br J Cancer. 2022 Sep 22. pii: 10.1038/s41416-022-01981.
    PubMed     Abstract available
    
    
    
21. CHEN Y, Wang DD, Wu YP, Su D, et al
    Correction To: MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells.
    Br J Cancer. 2022 Sep 15. pii: 10.1038/s41416-022-01984.
    PubMed    
    
    
    
22. ABIKO K, Hamanishi J, Matsumura N, Mandai M, et al
    Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after "IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer".
    Br J Cancer. 2022 Sep 6. pii: 10.1038/s41416-022-01960.
    PubMed     Abstract available
    
    
    August 2022
23. GAHLAWAT AW, Witte T, Haarhuis L, Schott S, et al
    A novel circulating miRNA panel for non-invasive ovarian cancer diagnosis and prognosis.
    Br J Cancer. 2022 Aug 5. pii: 10.1038/s41416-022-01925.
    PubMed     Abstract available
    
    
    July 2022
24. MUSACCHIO L, Califano D, Bartoletti M, Arenare L, et al
    Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
    Br J Cancer. 2022 Jul 22. pii: 10.1038/s41416-022-01897.
    PubMed     Abstract available
    
    
    
25. NICHOLSON HA, Sawers L, Clarke RG, Hiom KJ, et al
    Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer.
    Br J Cancer. 2022 Jul 1. pii: 10.1038/s41416-022-01899.
    PubMed     Abstract available
    
    
    June 2022
26. SASAMOTO N, Wang T, Townsend MK, Eliassen AH, et al
    Pre-diagnosis and post-diagnosis dietary patterns and survival in women with ovarian cancer.
    Br J Cancer. 2022 Jun 27. pii: 10.1038/s41416-022-01901.
    PubMed     Abstract available
    
    
    
27. BEINSE G, Just PA, Le Frere Belda MA, Laurent-Puig P, et al
    Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
    Br J Cancer. 2022 Jun 25. pii: 10.1038/s41416-022-01900.
    PubMed     Abstract available
    
    
    
28. KAMAT K, Krishnan V, Dorigo O
    Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer.
    Br J Cancer. 2022 Jun 24. pii: 10.1038/s41416-022-01887.
    PubMed     Abstract available
    
    
    
29. HOLLIS RL, Croy I, Churchman M, Bartos C, et al
    Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01874.
    PubMed     Abstract available
    
    
    
30. KOTSOPOULOS J, Zamani N, Rosen B, McLaughlin JR, et al
    Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer.
    Br J Cancer. 2022 Jun 16. pii: 10.1038/s41416-022-01840.
    PubMed     Abstract available
    
    
    May 2022
31. MENON U, Weller D, Falborg AZ, Jensen H, et al
    Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP).
    Br J Cancer. 2022 May 26. pii: 10.1038/s41416-022-01844.
    PubMed     Abstract available
    
    
    
32. CHEN T, Yu T, Zhuang S, Geng Y, et al
    Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
    Br J Cancer. 2022 May 26. pii: 10.1038/s41416-022-01836.
    PubMed     Abstract available
    
    
    
33. EL HELALI A, Plummer R, Jayson GC, Coyle VM, et al
    A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.
    Br J Cancer. 2022 May 14. pii: 10.1038/s41416-022-01780.
    PubMed     Abstract available
    
    
    April 2022
34. CREMONA M, Vandenberg CJ, Farrelly AM, Madden SF, et al
    BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors.
    Br J Cancer. 2022 Apr 30. pii: 10.1038/s41416-022-01823.
    PubMed     Abstract available
    
    
    
35. KOIZUME S, Takahashi T, Nakamura Y, Yoshihara M, et al
    Lipophagy-ICAM-1 pathway associated with fatty acid and oxygen deficiencies is involved in poor prognoses of ovarian clear cell carcinoma.
    Br J Cancer. 2022 Apr 21. pii: 10.1038/s41416-022-01808.
    PubMed     Abstract available
    
    
    
36. SHAKFA N, Li D, Nersesian S, Wilson-Sanchez J, et al
    The STING pathway: Therapeutic vulnerabilities in ovarian cancer.
    Br J Cancer. 2022 Apr 5. pii: 10.1038/s41416-022-01797.
    PubMed     Abstract available
    
    
    
37. KONSTANTINOPOULOS PA, Cheng SC, Supko JG, Polak M, et al
    Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
    Br J Cancer. 2022;126:1027-1036.
    PubMed     Abstract available
    
    
    March 2022
38. YOU B, Van Wagensveld L, Tod M, Sonke GS, et al
    Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
    Br J Cancer. 2022 Mar 31. pii: 10.1038/s41416-022-01732.
    PubMed     Abstract available
    
    
    
39. SEITZ S, Dreyer TF, Stange C, Steiger K, et al
    CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.
    Br J Cancer. 2022 Mar 21. pii: 10.1038/s41416-022-01763.
    PubMed     Abstract available
    
    
    
40. MORGAN RD, Burghel GJ, Flaum N, Bulman M, et al
    BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
    Br J Cancer. 2022 Mar 8. pii: 10.1038/s41416-022-01773.
    PubMed     Abstract available
    
    
    February 2022
41. ROQUE DM, Siegel ER, Buza N, Bellone S, et al
    Randomised phase II trial of weekly ixabepilone +/- biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
    Br J Cancer. 2022 Feb 11. pii: 10.1038/s41416-022-01717.
    PubMed     Abstract available
    
    
    January 2022
42. YE S, Li Q, Wu Y, Jiang W, et al
    Integrative genomic and transcriptomic analysis reveals immune subtypes and prognostic markers in ovarian clear cell carcinoma.
    Br J Cancer. 2022 Jan 18. pii: 10.1038/s41416-022-01705.
    PubMed     Abstract available
    
    
    
43. MUKAMA T, Fortner RT, Katzke V, Hynes LC, et al
    Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer.
    Br J Cancer. 2022 Jan 14. pii: 10.1038/s41416-021-01697.
    PubMed     Abstract available
    
    
    
44. SUN J, Yan C, Xu D, Zhang Z, et al
    Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy.
    Br J Cancer. 2022 Jan 11. pii: 10.1038/s41416-021-01692.
    PubMed     Abstract available
    
    
    December 2021
45. FOTOPOULOU C, Rockall A, Lu H, Lee P, et al
    Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC).
    Br J Cancer. 2021 Dec 18. pii: 10.1038/s41416-021-01662.
    PubMed     Abstract available
    
    
    November 2021
46. BYUN D, Hong S, Ryu S, Nam Y, et al
    Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose-response meta-analysis of prospective studies.
    Br J Cancer. 2021 Nov 12. pii: 10.1038/s41416-021-01625.
    PubMed     Abstract available
    
    
    
47. GUFFANTI F, Alvisi MF, Anastasia A, Ricci F, et al
    Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    Br J Cancer. 2021 Nov 3. pii: 10.1038/s41416-021-01609.
    PubMed     Abstract available
    
    
    October 2021
48. MURPHY AD, Morgan RD, Clamp AR, Jayson GC, et al
    The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
    Br J Cancer. 2021 Oct 29. pii: 10.1038/s41416-021-01605.
    PubMed     Abstract available
    
    
    
49. BLACKFORD AL, Childs EJ, Porter N, Petersen GM, et al
    A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO.
    Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01580.
    PubMed     Abstract available
    
    
    
50. SI S, Li J, Tewara MA, Li H, et al
    Identifying causality, genetic correlation, priority and pathways of large-scale complex exposures of breast and ovarian cancers.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01576.
    PubMed     Abstract available
    
    
    September 2021
51. CRISPIN-ORTUZAR M, Sala E
    Precision radiogenomics: fusion biopsies to target tumour habitats in vivo.
    Br J Cancer. 2021;125:778-779.
    PubMed     Abstract available
    
    
    June 2021
52. FENG JL, Dixon-Suen SC, Jordan SJ, Webb PM, et al
    Statin use and survival among women with ovarian cancer: an Australian national data-linkage study.
    Br J Cancer. 2021 Jun 16. pii: 10.1038/s41416-021-01460.
    PubMed     Abstract available
    
    
    May 2021
53. XU X, Wang Y, Bryce NS, Tang K, et al
    Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents.
    Br J Cancer. 2021 May 12. pii: 10.1038/s41416-021-01420.
    PubMed     Abstract available
    
    
    March 2021
54. LEPAGE CC, Palmer MCL, Farrell AC, Neudorf NM, et al
    Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer.
    Br J Cancer. 2021 Mar 17. pii: 10.1038/s41416-021-01317.
    PubMed     Abstract available
    
    
    
55. ZHANG X, Ling MT, Feng H, Wong YC, et al
    Retraction Note to: Id-1 stimulates cell proliferation through activation of EGFR in ovarian cancer cells.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01322.
    PubMed    
    
    
    
56. ARTHUR RS, Dannenberg AJ, Kim M, Rohan TE, et al
    The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-020-01210.
    PubMed     Abstract available
    
    
    February 2021
57. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available
    
    
    
58. HAYASHI T, Konishi I
    Correlation of anti-tumour drug resistance with epigenetic regulation.
    Br J Cancer. 2021;124:681-682.
    PubMed     Abstract available
    
    
    January 2021
59. LU H, Cunnea P, Nixon K, Rinne N, et al
    Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer.
    Br J Cancer. 2021 Jan 21. pii: 10.1038/s41416-020-01252.
    PubMed     Abstract available
    
    
    
60. SALAS-BENITO D, Conde E, Tamayo-Uria I, Mancheno U, et al
    The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1(+) tumour-infiltrating lymphocytes.
    Br J Cancer. 2021 Jan 5. pii: 10.1038/s41416-020-01218.
    PubMed     Abstract available
    
    
    
61. WINFIELD JM, Wakefield JC, Brenton JD, AbdulJabbar K, et al
    Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis.
    Br J Cancer. 2021 Jan 4. pii: 10.1038/s41416-020-01217.
    PubMed     Abstract available
    
    
    December 2020
62. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available
    
    
    November 2020
63. YAN S, Xuan J, Brajanovski N, Tancock MRC, et al
    The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
    Br J Cancer. 2020 Nov 11. pii: 10.1038/s41416-020-01158.
    PubMed     Abstract available
    
    
    October 2020
64. MILLINGTON K, Hayes K, Pilcher S, Roberts S, et al
    A serous borderline ovarian tumour in a transgender male adolescent.
    Br J Cancer. 2020 Oct 27. pii: 10.1038/s41416-020-01129.
    PubMed     Abstract available
    
    
    September 2020
65. KIM HS, Park SY, Park CY, Kim YT, et al
    A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer.
    Br J Cancer. 2020 Sep 30. pii: 10.1038/s41416-020-01098.
    PubMed     Abstract available
    
    
    July 2020
66. METCALFE KA, Price MA, Mansfield C, Hallett DC, et al
    Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis.
    Br J Cancer. 2020;123:268-274.
    PubMed     Abstract available
    
    
    June 2020
67. VAN WEELDEN WJ, van der Putten LJM, Inda MA, van Brussel A, et al
    Oestrogen receptor pathway activity is associated with outcome in endometrial cancer.
    Br J Cancer. 2020 Jun 8. pii: 10.1038/s41416-020-0925.
    PubMed     Abstract available
    
    
    May 2020
68. BOCHNER F, Fellus-Alyagor L, Ketter D, Golani O, et al
    Bimodal magnetic resonance and optical imaging of extracellular matrix remodelling by orthotopic ovarian tumours.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0878.
    PubMed     Abstract available
    
    
    April 2020
69. SKOLD C, Bjorge T, Ekbom A, Engeland A, et al
    Pregnancy-related risk factors for sex cord-stromal tumours and germ cell tumours in parous women: a registry-based study.
    Br J Cancer. 2020 Apr 27. pii: 10.1038/s41416-020-0849.
    PubMed     Abstract available
    
    
    
70. MONTFORT A, Owen S, Piskorz AM, Supernat A, et al
    Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma.
    Br J Cancer. 2020 Apr 6. pii: 10.1038/s41416-020-0822.
    PubMed     Abstract available
    
    
    February 2020
71. MASOODI T, Siraj S, Siraj AK, Azam S, et al
    Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases.
    Br J Cancer. 2020 Feb 26. pii: 10.1038/s41416-020-0763.
    PubMed     Abstract available
    
    
    
72. BERG HF, Ju Z, Myrvold M, Fasmer KE, et al
    Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma.
    Br J Cancer. 2020 Feb 10. pii: 10.1038/s41416-020-0745.
    PubMed     Abstract available
    
    
    
73. ROBERTS C, Strauss VY, Kopijasz S, Gourley C, et al
    Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
    Br J Cancer. 2020;122:483-490.
    PubMed     Abstract available
    
    
    December 2019
74. GENESTIE C, Blanc-Durand F, Auguste A, Pautier P, et al
    Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours.
    Br J Cancer. 2019 Dec 17. pii: 10.1038/s41416-019-0687.
    PubMed     Abstract available
    
    
    
75. BENGTSEN MB, Veres K, Norgaard M
    First-time postmenopausal bleeding as a clinical marker of long-term cancer risk: A Danish Nationwide Cohort Study.
    Br J Cancer. 2019 Dec 6. pii: 10.1038/s41416-019-0668.
    PubMed     Abstract available
    
    
    November 2019
76. TUNA M, Ju Z, Yoshihara K, Amos CI, et al
    Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers.
    Br J Cancer. 2019 Nov 29. pii: 10.1038/s41416-019-0654.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: